About Eligo bioscience
Eligo Bioscience: Revolutionizing Healthcare with In Vivo Gene Editing Technologies
Eligo Bioscience is a biotechnology company that is dedicated to revolutionizing healthcare by deploying in vivo gene editing technologies against microbiome targets. The company's mission is to address diseases with high unmet needs, and it has been making significant strides in this regard.
The microbiome refers to the collection of microorganisms that live on and inside our bodies. These microorganisms play a crucial role in maintaining our health, but when they become imbalanced or disrupted, they can lead to a range of diseases. Eligo Bioscience's approach involves using gene editing technologies to selectively target and modify specific bacteria within the microbiome.
One of the key advantages of this approach is its precision. Unlike traditional antibiotics, which can kill both harmful and beneficial bacteria indiscriminately, Eligo Bioscience's technology allows for targeted interventions that only affect specific strains of bacteria. This means that patients can receive treatment without disrupting their overall microbiome balance.
Eligo Bioscience has developed a proprietary platform called "CRISPR-enabled Bacteriophages" (crPhage) that combines CRISPR-Cas technology with bacteriophages - viruses that infect bacteria - to deliver targeted gene editing payloads directly into bacterial cells. This platform has shown promising results in preclinical studies for a range of indications, including urinary tract infections (UTIs), inflammatory bowel disease (IBD), and colorectal cancer.
In addition to its crPhage platform, Eligo Bioscience is also developing other innovative approaches for targeting the microbiome. For example, the company has developed "smart capsules" - ingestible devices containing engineered bacteria - that can detect and respond to changes in the gut environment.
Eligo Bioscience was founded in 2014 by Drs Xavier Duportet and David Bikard at Institut Pasteur in Paris. Since then, the company has raised over $40 million in funding from investors such as Khosla Ventures, Seventure Partners, and Illumina Ventures. The company has also established partnerships with leading pharmaceutical companies such as GSK and AbbVie to develop its technology for specific indications.
Eligo Bioscience's innovative approach to microbiome-targeted gene editing has the potential to transform healthcare by providing more precise and effective treatments for a range of diseases. With its cutting-edge technology and strong partnerships, the company is well-positioned to lead this emerging field and make a significant impact on patients' lives.